Viking Therapeutics

VKTX on Nasdaq. Viking Therapeutics develops drugs for obesity and metabolic diseases and sells none yet. Market value $3.7bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to September 2026. Some use the latest annual report instead, as marked. Quality checks use five annual reports, the latest for the year to December 2025.

We can't read total debt from the filing, so debt is left out.

Cash flow or capital spending isn't reported, so free cash flow is unknown.

Should I look at this?

Not a fit for our list right now

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
annual report to December 2025
n/a

We could not compute this from the filings.

Price to profit
past 12 months to September 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: not known. Price score: 16 of 100. Our list needs 70 on quality and 60 on price.

$24.77 a share, 4% above its 1-year low

Over the past year the price has ranged from $23.82 to $43.10.

Pays no dividend

Prices from Friday’s close (20 November).

Five years of cash, in billions

n/a
n/a
n/a
n/a
n/a
20212022202320242025
Revenue
$0$0$0$0$0
Operating margin
n/an/an/an/an/a
Debt to equity
n/an/an/an/an/a
Shares outstanding
0.08bn0.10bn0.11bn0.11bn0.13bn

Health checks

  • Free cash flow positiveNot enough data
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)1 of 7 checks we could run
  • Profit backed by cash (accruals)Yes
  • DebtUnknown
  • Revenue growth, five yearsUnknown
  • Buying back its own sharesNo, 66% more shares since 2021

The quarter to September 2026

How the business did, compared with the same quarter a year earlier.

  • A loss of $183 million, compared with a loss of $91 million a year ago.
  • 5% more shares than a year ago. Each share owns a bit less of the company.
  • Sales did not grow on a year ago in any of the last 4 quarters.
Profit by quarter
Profit by quarter
Quarter toAmount
December 2024-$35m
March 2025-$46m
June 2025-$66m
September 2025-$91m
December 2025-$158m
March 2026-$158m
June 2026-$128m
September 2026-$183m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
11 February 2026
Next quarterly (estimated, 10-Q)
28 January 2027

Who owns it

1 long-term investor we follow owns it, unchanged from 1 last quarter. 434 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

2 investors own more than 5%.

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 1 insider bought $149,913 of shares on the open market. 4 sold $18m.

  • Lian Brian
    President & CEO, Director
    Sold
    Date
    29 July 2026
    Shares
    148,517
    Price
    $33.32
    Value
    $5m
  • ZANTE GREG
    Chief Financial Officer
    Sold
    Date
    29 July 2026
    Shares
    21,217
    Price
    $33.47
    Value
    $710,141
  • Mancini Marianna
    Chief Operating Officer
    Sold
    Date
    29 July 2026
    Shares
    18,217
    Price
    $33.47
    Value
    $609,636
  • Aubuchon Neil William
    Chief Commercial Officer
    Bought
    Date
    10 March 2026
    Shares
    4,475
    Price
    $33.50
    Value
    $149,913
  • ZANTE GREG
    Chief Financial Officer
    Sold
    Date
    5 January 2026
    Shares
    57,661
    Price
    $32.90
    Value
    $2m
  • Mancini Marianna
    Chief Operating Officer
    Sold
    Date
    5 January 2026
    Shares
    57,661
    Price
    $32.97
    Value
    $2m
  • Lian Brian
    President & CEO, Director
    Sold
    Date
    5 January 2026
    Shares
    233,409
    Price
    $32.96
    Value
    $8m
  • FOEHR MATTHEW W
    Director
    Sold
    Date
    2 January 2026
    Shares
    16,000
    Price
    $35.11
    Value
    $561,760

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 11 Feb 2026, plus the 10-Q filed 29 Oct 2026 and 6 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.